Multimodal imaging with 18F-FDG PET and cerenkov luminescence imaging after MLN4924 treatment in a human lymphoma xenograft model

Journal of Nuclear Medicine

Volumn 52, Issue 11, 2011, Pages 1764-1769

  Robertson, Robbie ^a   Germanos, Melissa Saylor ^a   Manfredi, Mark G ^a   Smith, Peter G ^a   Silva, Matthew D ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

Cerenkov luminescence imaging; MLN4924; NAE inhibition; PET

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; MLN 4924; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CERENKOV LUMINESCENCE IMAGING; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; FEMALE; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; LARGE CELL LYMPHOMA; LIGHT IRRADIANCE; LUMINESCENCE; LYMPHOMA CELL LINE; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; REPEATED DRUG DOSE; SENSITIVITY ANALYSIS; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CYCLOPENTANES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUMINESCENT MEASUREMENTS; LYMPHOMA; MICE; MOLECULAR IMAGING; POSITRON-EMISSION TOMOGRAPHY; PYRIMIDINES;

EID: 80455168427     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.091710     Document Type: Article

References (30)

1. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer. 2005;5:845-856. (Pubitemid 41746029)
2. Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov. 2003;2:566-580. (Pubitemid 37361748)
3. Seddon BM, Workman P. The role of functional and molecular imaging in cancer drug discovery and development. Br J Radiol. 2003;76(spec no 2):S128-S138. (Pubitemid 39530306)
4. Kelloff GJ, Krohn KA, Larson SM, et al. The progress and promise of molecular imaging probes in oncologic drug development. Clin Cancer Res. 2005;11:7967-7985. (Pubitemid 41698738)
5. Pien HH, Fischman AJ, Thrall JH, et al. Using imaging biomarkers to accelerate drug development and clinical trials. Drug Discov Today. 2005;10:259-266. (Pubitemid 40222219)
6. Hargreaves RJ. The role of molecular imaging in drug discovery and development. Clin Pharmacol Ther. 2008;83:349-353.
7. Kelloff GJ, Hoffman JM, Johnson B, et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res. 2005;11:2785-2808. (Pubitemid 40525178)
8. Contractor KB, Aboagye EO. Monitoring predominantly cytostatic treatment response with 18F-FDG PET. J Nucl Med. 2009;50(suppl 1):97S-105S.
9. Warburg O. On the origin of cancer cells. Science. 1956;123:309-314.
10. Kim JW, Dang CV. Cancer's molecular sweet tooth and the Warburg effect. Cancer Res. 2006;66:8927-8930. (Pubitemid 44521105)
11. Gillies RJ, Robey I, Gatenby RA. Causes and consequences of increased glucose metabolism of cancers. J Nucl Med. 2008;49(suppl 2):24S-42S. (Pubitemid 351948035)
12. Plathow C, Weber WA. Tumor cell metabolism imaging. J Nucl Med. 2008;49 (suppl 2):43S-63S. (Pubitemid 351948036)
13. Czernin J, Weber WA, Herschman HR. Molecular imaging in the development of cancer therapeutics. Annu Rev Med. 2006;57:99-118. (Pubitemid 43261981)
14. Willmann JK, van Bruggen N, Dinkelborg LM, et al. Molecular imaging in drug development. Nat Rev Drug Discov. 2008;7:591-607. (Pubitemid 351927724)
15. Robertson R, Germanos MS, Li C, et al. Optical imaging of Cerenkov light generation from positron-emitting radiotracers. Phys Med Biol. 2009;54:N355-N365.
16. Jelley J. V Cerenkov radiation and its applications. Br J Appl Phys. 1955;6:227-232.
17. Elrick RH, Parker RP. The use of Cerenkov radiation in the measurement of betaemitting radionuclides. Int J Appl Radiat Isot. 1968;19:263-271.
18. Ross H. H Measurement of b-emitting nuclides using Cerenkov radiation. Anal Chem. 1969;41:1260-1265.
19. L'Annunciata MF. Handbook of Radioactivity Analysis. San Diego, CA: Academic; 2003.
20. Liu H, Ren G, Miao Z, et al. Molecular optical imaging with radioactive probes. PLoS ONE. 2010;5:e9470.
21. Li C, Mitchell GS, Cherry SR. Cerenkov luminescence tomography for smallanimal imaging. Opt Lett. 2010;35:1109-1111.
22. Cho JS, Taschereau R, Olma S, et al. Cerenkov radiation imaging as a method for quantitative measurements of beta particles in a microfluidic chip. Phys Med Biol. 2009;54:6757-6771.
23. Spinelli AE, D'Ambrosio D, Calderan L, et al. Cerenkov radiation allows in vivo optical imaging of positron emitting radiotracers. Phys Med Biol. 2010;55:483-495.
24. Ruggiero A, Holland JP, Lewis JS, Grimm J. Cerenkov luminescence imaging of medical isotopes. J Nucl Med. 2010;51:1123-1130.
25. Soucy TA, Smith PG, Milhollen MA, et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature. 2009;458:732-736.
26. Soucy TA, Smith PG, Rolfe M. Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer. Clin Cancer Res. 2009;15:3912-3916.
27. Brownell JE, Sintchak MD, Gavin JM, et al. Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ. Mol Cell. 2010;37:102-111.
28. Milhollen MA, Traore T, Adams-Duffy J, et al. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-kB-dependent lymphoma. Blood. 2010;116:1515-1523.
29. Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academy Press; 1996.
30. Mobley J, Vo-Dinh T, Tuchin VV. Optical properties of tissue. In: Biomedical Photonics Handbook. 2nd ed. Boca Raton, FL: CRC Press; 2003.